<PAGE>
--------------------------------
/ OMB APPROVAL /
--------------------------------
/ OMB Number: 3235-0145 /
/ Expires: November 30, 1999 /
/ Estimated average burden /
/ hours per response ... 14.90 /
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
NORTHWEST BANCORPORATION, INC.
________________________________________________________________________________
(Name of Issuer)
Common Stock
________________________________________________________________________________
(Title of Class of Securities)
667337109
_______________________________________________________________
(CUSIP Number)
RALPH BERG, JR., M.D.,
5112 S. St. Andrews Lane, Spokane, WA 99223 (509) 448-0725
________________________________________________________________________________
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
January 14, 2000
_______________________________________________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of (S)(S)240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [_]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See (S)240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Potential persons who are to respond to the collection of information contained
in this form are nor required to respond unless the form displays a currently
valid OMB control number.
<PAGE>
CUSIP NO. 667337109
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSONS.
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
RALPH BERG, JR., M.D.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
2 (a) N/A
(b) N/A
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS (SEE INSTRUCTIONS)
4
PF
- ------------------------------------------------------------------------------
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)
5 N/A
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
U.S.A.
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
91,327
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
91,327
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
91,327
- ------------------------------------------------------------------------------
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12 (SEE INSTRUCTIONS)
N/A
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
5.8%/1/
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
14
IN
- ------------------------------------------------------------------------------
- ---------------
/1/ This percentage is based upon a number of outstanding shares set forth
in the most recent financial statement prepared by the Issuer for presentation
to its Board of directors at its next meeting on February 15, 2000 (1,575,127 as
of January 18, 2000) which Dr. Berg has no reason to believe is not current.
2
<PAGE>
Item 1. Security and Issuer
The class of equity securities to which this statement relates is common
stock, without par value, of the Issuer, Northwest Bancorporation, Inc. The
address of the Issuer is 421 West Riverside Avenue, Spokane, Washington 99201.
Item 2. Identity and Background
a. Ralph Berg, Jr., M.D.
b. 5112 S. St. Andrews Lane, Spokane, WA 99223
c. Retired cardiovascular surgeon.
d. No criminal convictions.
e. Not a party to any civil proceedings pertaining to federal or state
securities laws within the last five years.
f. U.S.A. citizen.
Item 3. Source and Amount of Funds or Other Consideration
The 91,327 shares of common stock owned beneficially and of record by Dr.
Berg were acquired with personal funds.
Item 4. Purpose of Transaction
The shares of common stock and warrants were acquired for investment
purposes. Dr. Berg has no current plans or proposals which relate to or would
result in:
a. The acquisition by any person of additional securities of the Issuer,
or the disposition of securities of the Issuer;
b. An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its
subsidiaries;
c. A sale or transfer of a material amount of assets of the Issuer or any
of its subsidiaries;
d. Any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number of term
of directors or to fill any existing vacancies on the board;
e. Any material change in the present capitalization or dividend policy
of the Issuer;
f. Any other material change in the Issuer's business or corporate
structure;
g. Changes in the Issuer's charter, bylaws or instruments corresponding
thereto or other actions which may impede the acquisition of control
of the Issuer by any person;
3
<PAGE>
h. Causing a class of securities of the Issuer to be delisted from a
national securities exchange or to cease to be authorized to be quoted
in an inter-dealer quotation system of a registered national
securities association;
i. Causing a class of equity securities of the Issuer to become eligible
for termination of registration pursuant to Section 12(g)(4) of the
Act; or
j. Any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer
a. Dr. Berg beneficially owns 91,327 shares, constituting 5.8%/1/ of the
outstanding shares of common stock of the Issuer.
b. Sole Voting Power: 91,327;
------
Sole Dispositive Power: 91,327;
------
c. None.
d. Not applicable.
e. Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer
None.
- ---------------
/1/ This percentage is based upon a number of outstanding shares set forth
in the most recent financial statement prepared by the Issuer for presentation
to its Board of directors at its next meeting on February 15, 2000 (1,575,127 as
of January 18, 2000) which Dr. Berg has no reason to believe is not current.
4
<PAGE>
Item 7. Material to Be Filed as Exhibits
None.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: January 28, 2000
Signatures: /s/ Ralph Berg, Jr., M.D.
---------------------------------
Ralph Berg, Jr., M.D.
Attention: International misstatements or omissions of fact constitute
Federal criminal violations (See U.S.C. 1001).
5
